These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34380434)

  • 21. Small molecules from antibody pharmacophores (SMAbPs) as a hit identification workflow for immune checkpoints.
    Abdel-Rahman SA; Gabr MT
    Sci Adv; 2024 Oct; 10(42):eadq5540. PubMed ID: 39413175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VISTA is an immune checkpoint molecule for human T cells.
    Lines JL; Pantazi E; Mak J; Sempere LF; Wang L; O'Connell S; Ceeraz S; Suriawinata AA; Yan S; Ernstoff MS; Noelle R
    Cancer Res; 2014 Apr; 74(7):1924-32. PubMed ID: 24691993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA.
    Mehta N; Maddineni S; Kelly RL; Lee RB; Hunter SA; Silberstein JL; Parra Sperberg RA; Miller CL; Rabe A; Labanieh L; Cochran JR
    Sci Rep; 2020 Sep; 10(1):15171. PubMed ID: 32938950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers.
    Wang G; Tai R; Wu Y; Yang S; Wang J; Yu X; Lei L; Shan Z; Li N
    Cytokine Growth Factor Rev; 2020 Apr; 52():1-14. PubMed ID: 32057701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy.
    Im E; Sim DY; Lee HJ; Park JE; Park WY; Ko S; Kim B; Shim BS; Kim SH
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):1066-1075. PubMed ID: 34428551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.
    Wang L; Rubinstein R; Lines JL; Wasiuk A; Ahonen C; Guo Y; Lu LF; Gondek D; Wang Y; Fava RA; Fiser A; Almo S; Noelle RJ
    J Exp Med; 2011 Mar; 208(3):577-92. PubMed ID: 21383057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VISTA: A promising target for overcoming immune evasion in gynecologic cancers.
    Liu S; Ji F; Ding Y; Ding B; Feng S; Brennick C; Lin H; Zhang T; Shen Y
    Int Immunopharmacol; 2024 Sep; 138():112655. PubMed ID: 38986302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VISTA: A Promising Target for Cancer Immunotherapy?
    Tagliamento M; Agostinetto E; Borea R; Brandão M; Poggio F; Addeo A; Lambertini M
    Immunotargets Ther; 2021; 10():185-200. PubMed ID: 34189130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and structure-activity relationship of PD-1/PD-L1 inhibitors with a benzo[d]isoxazole scaffold.
    Huang X; Chen H; Dai X; Xu M; Wang K; Feng Z
    Bioorg Med Chem Lett; 2021 Nov; 52():128403. PubMed ID: 34610423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
    Kopalli SR; Kang TB; Lee KH; Koppula S
    Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy.
    Shekari N; Shanehbandi D; Kazemi T; Zarredar H; Baradaran B; Jalali SA
    Cancer Cell Int; 2023 Nov; 23(1):265. PubMed ID: 37936192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VISTA is an acidic pH-selective ligand for PSGL-1.
    Johnston RJ; Su LJ; Pinckney J; Critton D; Boyer E; Krishnakumar A; Corbett M; Rankin AL; Dibella R; Campbell L; Martin GH; Lemar H; Cayton T; Huang RY; Deng X; Nayeem A; Chen H; Ergel B; Rizzo JM; Yamniuk AP; Dutta S; Ngo J; Shorts AO; Ramakrishnan R; Kozhich A; Holloway J; Fang H; Wang YK; Yang Z; Thiam K; Rakestraw G; Rajpal A; Sheppard P; Quigley M; Bahjat KS; Korman AJ
    Nature; 2019 Oct; 574(7779):565-570. PubMed ID: 31645726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting cryptic-orthosteric site of PD-L1 for inhibitor identification using structure-guided approach.
    Mittal L; Tonk RK; Awasthi A; Asthana S
    Arch Biochem Biophys; 2021 Nov; 713():109059. PubMed ID: 34673001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy.
    Huang X; Zhang X; Li E; Zhang G; Wang X; Tang T; Bai X; Liang T
    J Hematol Oncol; 2020 Jun; 13(1):83. PubMed ID: 32600443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.
    Li K; Tian H
    J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tackling molecular targets beyond PD-1/PD-L1: Novel approaches to boost patients' response to cancer immunotherapy.
    Omar HA; Tolba MF
    Crit Rev Oncol Hematol; 2019 Mar; 135():21-29. PubMed ID: 30819443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
    Yang Y; Wang K; Chen H; Feng Z
    Eur J Med Chem; 2021 Feb; 211():113001. PubMed ID: 33272783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New emerging targets in cancer immunotherapy: the role of VISTA.
    Tagliamento M; Bironzo P; Novello S
    ESMO Open; 2020 Jun; 4(Suppl 3):e000683. PubMed ID: 32554470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules.
    Yang J; Hu L
    Med Res Rev; 2019 Jan; 39(1):265-301. PubMed ID: 30215856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of Benzo[
    Wang K; Cai S; Cheng Y; Qi Z; Ni X; Zhang K; Xiao Y; Zhang X; Wang T
    J Med Chem; 2024 Oct; 67(20):18526-18548. PubMed ID: 39389791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.